#United States #New York #Class Action #Pomerantz Law Firm #Altimmune Inc.

Pomerantz Law Firm's Class Action Against Altimmune, Inc.

In a significant move for investors, Pomerantz LLP has initiated a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT), which raises critical questions about the company's business practices and their impact on shareholders. As an esteemed firm recognized for its role in corporate and securities class litigation, Pomerantz continues its mission to advocate for investors who have suffered losses due to potential securities fraud and other unlawful business operations.

Important Details

The lawsuit serves as a wake-up call for those who may have incurred losses while holding Altimmune securities. Investors are encouraged to contact Danielle Peyton at Pomerantz either through email or phone to join the class action. The deadline to officially ask the Court to designate you as Lead Plaintiff for the class action is set for October 6, 2025. This is a crucial date for anyone affected by the alleged misconduct of Altimmune's leadership.

On June 26, 2025, Altimmune released details about the topline results from its IMPACT Phase 2b MASH trial, which examined the drug Pemvidutide's effectiveness in treating MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) patients. Concerns arose as the results showed a lack of statistical significance in the primary endpoint concerning fibrosis reduction. Though a positive trend was reported, the higher-than-anticipated placebo response led many to question the trial's reliability. When pressed for comments about this disappointing outcome, company officials responded nonchalantly, indicating that they were looking toward a future Phase 3 trial for better results.

Following the press release, investor reactions were swift, leading to a dramatic plunge in Altimmune's stock price by $4.10, equivalent to 53.2%, closing at $3.61 per share. This plunge highlighted the volatility and uncertainty surrounding the company's future, raising alarm among shareholders.

About Pomerantz LLP

Founded by the late Abraham L. Pomerantz—an influential figure known as the dean of the class action bar—Pomerantz LLP has spent over 85 years fighting for justice for those affected by securities fraud and corporate misdeeds. The firm has successfully obtained notable damages on behalf of numerous class members, reinforcing its reputation as a leading advocate for the rights of the investing public.

In summary, the ongoing developments surrounding Altimmune underscore the necessity for investors to stay informed regarding legal proceedings and potential recovery avenues for their losses. By joining this class action, affected investors may play a significant role in holding Altimmune accountable for its alleged missteps and ensuring fair treatment in the securities marketplace.

For more information on joining the class action or to access the complaint document, interested parties can visit Pomerantz Law Firm's website. Now is the time for investors to take action and protect their rights.